BFK — Pharmesis International Income Statement
0.000.00%
Last trade - 00:00- SG$11.25m
- SG$13.37m
- CNY43.75m
Annual income statement for Pharmesis International, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 52.8 | 50.4 | 45.6 | 67.7 | 43.8 |
| Cost of Revenue | |||||
| Gross Profit | 25 | 24 | 20.8 | 24.1 | 15.8 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 49.6 | 52.6 | 49.6 | 58.5 | 47.1 |
| Operating Profit | 3.15 | -2.23 | -3.98 | 9.14 | -3.33 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2.12 | -3.16 | -4.86 | 8.44 | -4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.97 | -3.18 | -4.9 | 7.61 | -4.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.17 | -3.56 | -4.96 | 8.28 | -4.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.17 | -3.56 | -4.96 | 8.28 | -4.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.049 | -0.154 | -0.186 | 0.066 | -0.136 |
| Special Dividends per Share |